

Potential Disease-Modifying Therapeutics for Neurodegenerative Disorders

福永 浩司¹, Rae R. MATSUMOTO²

¹東北大院薬, ²College of Pharmacy, Touro University California

Development of iPS technology and immunotherapy are now central dogma in the big pharm for continuous growing pharmaceuticals. However, quality of life (QOL) in patients suffering from neurodegenerative disorders should be improved by development of disease-modifying drugs generated by collaboration with company and academia. This PSJ-AAPS joint symposium is focused on the improvement of drug bioavailability and drug development to modify the proteinopathy induced the neurodegenerative disorders. It is the good opportunity for young investigators to learn chemical biology for novel drug development in neuropharmacology.